{"brief_title": "Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD", "brief_summary": "The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.", "condition": ["Macular Degeneration"], "intervention_type": ["Drug", "Other"], "intervention_name": ["Anecortave Acetate 15 mg sterile suspension", "Photodynamic Therapy (PDT)"], "arm_group_label": ["Anecortave and Sham PDT", "PDT and Sham Anecortave Acetate", "Anecortave and Sham PDT", "PDT and Sham Anecortave Acetate"], "criteria": "Patients of any race, either gender, aged 50 years and above, diagnosed with subfoveal CNV due to AMD with best corrected logMAR visual acuity of 20/40 (snellen equivalent) to 20/400 (Snellen equivalent) in the study eye. Clinically relevant concomitant diseases will be excluded.", "gender": "All", "minimum_age": "50 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Wet form of age-related macular degeneration", "mesh_term": ["Macular Degeneration", "Verteporfin", "Anecortave"], "id": "NCT00041483"}